For decades, when doctors said "high clinical risk" and "early breast cancer" in the same breath, chemotherapy followed automatically. But a trial presented at the American Society of Clinical Oncology meeting in Chicago on May 30, 2026, is splitting apart what once seemed inseparable.
The OPTIMA trial tracked 4,400 patients across the United Kingdom, all diagnosed with early-stage estrogen receptor-positive, HER2-negative breast cancer and flagged as high clinical risk by traditional measures. Researchers wanted to know whether a simple genomic test could answer a question oncologists had never quite been able to — which patients actually need chemotherapy, and which would get the same outcome without it?
The test in question is Veracyte's Prosigna Breast Risk of Recurrence test. It analyzes gene expression patterns in tumor tissue already removed during surgery, returning a Risk of Recurrence score and a 10-year probability of distant recurrence. The goal was straightforward: distinguish patients whose tumors would respond to chemotherapy from those for whom the treatment would make no measurable difference.
The results were striking. Sixty-eight percent of the patients in the trial did not need chemotherapy at all.
This is not a marginal improvement. Breast cancer strikes hundreds of thousands of people annually in the United States alone, and similar numbers across Europe. The Prosigna test itself is not new — what OPTIMA provides is something more powerful: randomized data from over 4,400 participants showing that treatment guided by this test works just as well as the standard full regimen for patients previously assumed to need it.
In the trial, patients whose Prosigna scores came back low were assigned to endocrine therapy alone. Their outcomes tracked closely with those of patients who received the full chemotherapy protocol. No meaningful difference in recurrence rates. No difference in survival.
The significance lies in what this spares those 68 percent from experiencing. Chemotherapy for early breast cancer carries real costs: cardiac damage, neuropathy, heightened infection risk, and cognitive effects that can persist for years. For patients destined to have the same outcome regardless, these side effects represent suffering without benefit — a burden the test could now help avoid.
The OPTIMA trial also drew a clear line. The remaining 32 percent — those whose Prosigna scores indicated higher recurrence risk — still benefited from chemotherapy. This is not a claim that chemotherapy should be abandoned; it is a sorting mechanism. For more than two-thirds of the patients assessed, it was never necessary in the first place.
If clinical practice shifts in response to this trial, the impact could be transformative. A genomic test administered at diagnosis could tell the majority of high-risk breast cancer patients upfront that they do not need chemotherapy, sparing them months of treatment with serious side effects while preserving their health outcomes. At a population level, the number is staggering: tens of thousands of patients across the US and UK alone could potentially avoid unnecessary chemotherapy each year.
The trial represents a shift from assumption to evidence, from treating all high-risk patients the same way to tailoring treatment based on what their tumors actually say about their likelihood of response.